Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Robert de Wilton Marsh"'
Publikováno v:
Case Reports in Oncology, Vol 8, Iss 1, Pp 138-141 (2015)
Background: Irinotecan is commonly used in combination with oxaliplatin as a component of FOLFIRINOX chemotherapy for several gastrointestinal malignancies. The purpose of this case report is to describe a patient who developed acute paralysis and ap
Externí odkaz:
https://doaj.org/article/c1cae7d21c0d4a4fa7ca9e96d3bacaa5
Autor:
Robert de Wilton Marsh
Publikováno v:
Colorectal Liver Metastasis ISBN: 9783031093227
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d65a1b9eb67958779ffcf09e4ed57aa6
https://doi.org/10.1007/978-3-031-09323-4_35
https://doi.org/10.1007/978-3-031-09323-4_35
Autor:
Amikar Sehdev, Blase N. Polite, Hedy L. Kindler, Ahad Ali Sadiq, Jaclyn D Peterson, Smita S. Joshi, Mark M. Zalupski, Andrea Amico, Daniel V.T. Catenacci, Theodore Karrison, Vincent J. Picozzi, James L. Wade, Manish R. Sharma, Mark Kozloff, Robert de Wilton Marsh
Publikováno v:
Clinical Cancer Research. 26:18-24
Purpose: 5-Fluorouracil (5-FU)/leucovorin, irinotecan, and nab-paclitaxel are all active agents in gastrointestinal cancers; the combination, FOLFIRABRAX, has not been previously evaluated. UDP Glucuronosyltransferase 1A1 (UGT1A1) clears SN-38, the a
Autor:
Robert de Wilton Marsh, Blase N. Polite, Hedy L. Kindler, Kenisha Allen, Mark Kozloff, Manish R. Sharma, Daniel V.T. Catenacci, Grace K. Suh, Smita S. Joshi, Theodore Karrison
Publikováno v:
Cancer. 125:1629-1636
BACKGROUND FOLFIRINOX (5-fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) is an effective but toxic therapy for pancreatic cancer. UGT1A1 (UDP glucuronosyltransferase 1A1) eliminates the active metabolite of irinotecan. Polymorphisms reduce
Autor:
Nicholas R. Suss, Faris Murad, Kevin K. Roggin, Darren S. Bryan, Marshall S. Baker, Robert de Wilton Marsh, David J. Winchester, Richard A. Prinz, Mark S. Talamonti, David J. Bentrem, Chi Hsiung Wang, Kristine Kuchta, Susan J. Stocker
Publikováno v:
Surgery. 163:1047-1052
Background The benefit of adding external beam radiation to adjuvant chemotherapy in patients that have undergone a margin positive resection for early stage, pancreatic ductal adenocarcinoma has not been determined definitively. Methods The National
Autor:
Robert de Wilton Marsh, Chi Wang, Blase N. Polite, Hedy L. Kindler, Mitchell C. Posner, Jeffrey B. Matthews, Daniel V.T. Catenacci, Mark Kozloff, Marshall S. Baker, Mark S. Talamonti, Kevin K. Roggin, Michele Britto
Publikováno v:
Journal of Surgical Oncology. 117:354-362
Background and Objectives Surgery followed by gemcitabine and/or a fluoropyrimidine is standard therapy for resectable PDAC. mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2 Day 1, 5-FU 2400 mg/m2 × 48 h IV, peg-filgrast
Autor:
Richard A. Prinz, Waseem Lutfi, Kevin K. Roggin, Robert de Wilton Marsh, Susan J. Stocker, Chi Hsiung Wang, Mark S. Talamonti, David J. Bentrem, Marshall S. Baker, David J. Winchester, Olga Kantor
Publikováno v:
The American Journal of Surgery. 213:521-525
Neoadjuvant protocols for early stage pancreatic adenocarcinoma (PDAC) frequently involve external beam radiation used in combination with systemic chemotherapy. The benefit of radiation in these protocols has not been determined.We examined patients
Autor:
Richard A. Prinz, Robert de Wilton Marsh, Chi-Hsiung Wang, Waseem Lutfi, Mark S. Talamonti, Marshall S. Baker, David J. Winchester, Olga Kantor
Publikováno v:
Surgery. 160:1466-1476
The absolute benefit of adjuvant external beam radiation therapy after a margin-negative resection in early stage pancreatic cancer has not been determined.We queried the National Cancer Data Base for patients with pathologic stage I-II pancreatic ad
Autor:
Richard A. Prinz, Erik Liederbach, Waseem Lutfi, David J. Winchester, Olga Kantor, David J. Bentrem, Robert de Wilton Marsh, Kevin K. Roggin, Marshall S. Baker, Chi Hsiung Wang, Susan J. Stocker, Mark S. Talamonti
Publikováno v:
Surgery. 160:714-724
The value of neoadjuvant chemotherapy in the treatment of early stage pancreatic cancer is not yet clear.We evaluated patients from the National Cancer Data Base who underwent pancreaticoduodenectomy for clinical stage I and II pancreatic adenocarcin
Autor:
Spencer C. Behr, Terence M. Williams, Qian Shi, Brian M. Wolpin, Jeffrey P. Meyers, Eric A. Collisson, Eileen M. O'Reilly, Alan P. Venook, Gina M. Vaccaro, Syed A. Ahmad, Robert de Wilton Marsh, Matthew H.G. Katz, James Lewis Leenstra, Jeffrey A. Meyerhardt, Wendy L. Frankel, Lawrence H. Schwartz, Michael Choung, Joseph M. Herman
Publikováno v:
Journal of Clinical Oncology. 39:377-377
377 Background: Neoadjuvant therapy has been associated with a median overall survival (OS) of 18 – 23 months (mo) in patients (pts) with BR pancreatic ductal adenocarcinoma (PDAC). To establish reference regimens to which novel treatments can be c